Neuroleptic malignant syndrome in 12 of 9,792 Chinese inpatients exposed to neuroleptics: a prospective study.
In a prospective study of an estimated 9,792 inpatients treated with neuroleptic medication at a large Chinese psychiatric hospital, 12 patients developed neuroleptic malignant syndrome. The estimated prevalence of neuroleptic malignant syndrome in these psychiatric inpatients was 1.23/1,000 (95% confidence interval = 0.63/1,000 to 2.14/1,000). Unlike other investigators, the authors found that young adulthood, nonschizophrenic illness, oral high-potency neuroleptics, and concurrent use of lithium were not important risk factors for neuroleptic malignant syndrome. However, depot fluphenazine decanoate, particularly if used without an antiparkinsonian agent, was a risk factor.
Deng
M Z
MZ
Guangzhou City Psychiatric Hospital, Guangdong, People's Republic of China.
Chen
G Q
GQ
Phillips
M R
MR
D000328:Adult; D000978:Antiparkinson Agents / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000009:adverse effects*; D002681:China / Q000208:ethnology; D016001:Confidence Intervals; D003692:Delayed-Action Preparations; D005260:Female; D005476:Fluphenazine / Q000009:adverse effects / Q000031:analogs & derivatives; D006760:Hospitalization; D006778:Hospitals, Psychiatric; D006801:Humans; D008297:Male; D001523:Mental Disorders / Q000188:drug therapy*; D009459:Neuroleptic Malignant Syndrome / Q000453:epidemiology* / Q000208:ethnology / Q000209:etiology; D015995:Prevalence; D011446:Prospective Studies; D012307:Risk Factors
D000978:Antiparkinson Agents; D014150:Antipsychotic Agents; D003692:Delayed-Action Preparations; C011825:fluphenazine depot; D005476:Fluphenazine